By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Osmotica Pharmaceutical 

1205 Culbreth Drive
Suite 200
Wilmington  North Carolina  28405  U.S.A.
Phone: 910-509-0114 Fax: 910-509-0115



Company News
Osmotica Pharmaceutical Announces FDA Acceptance Of Filing For Ontinua ER For Alleviation Of Spasticity Resulting From Multiple Sclerosis And Strong Advancement In The Clinical Program For Osmolex ER 9/29/2015 11:42:06 AM
Osmotica Pharmaceutical Announces Its Second Late Stage NDA Asset, OS-320 (“Osmolex ER”), Has Been Awarded Orphan Drug Status By The United States FDA 7/22/2015 10:13:37 AM
Advancements In Osmotica Pharmaceutical’s CNS Pipeline For Spasticity In MS Patients And LID In Parkinson’s Patients 7/8/2015 8:16:17 AM
Osmotica Pharmaceutical Announces the Commercial Launch of Its KHEDEZLA (desvenlafaxine) Extended-Release Tablets, 50 mg and 100 mg 9/27/2013 9:34:19 AM
Osmotica Pharmaceutical Appoints Praveen Tyle, Ph.D. as President and CEO 1/4/2013 7:07:32 AM
Osmotica Pharmaceutical Announces Initiation of Phase III Studies With Arbaclofen ER Tablets 12/10/2012 9:41:50 AM
Osmotica Pharmaceutical Announces the Appointment of Praveen Tyle, PhD as Executive Vice President and Chief Scientific Officer 10/15/2012 10:17:24 AM
Osmotica Pharmaceutical and Panacea Biotech Ltd. Announce Strategic Alliance Agreement 9/11/2012 10:15:30 AM
Osmotica Pharmaceutical Announces the Appointment of Darren Alkins as Executive Vice President 9/10/2012 9:34:04 AM
Osmotica Pharmaceutical to Create 156 Jobs in Georgia 8/12/2011 7:39:36 AM